Uploaded May 2026 | Updated September 2026, 2 weeks ago
Samuel Rodriques, Co-founder of Edison Scientific, left physics because there were no unsolved problems left.
Instead, he built an AI scientist named Kosmos to cure every disease, solve aging, and map the human brain.
In this episode:
- The cure his AI proposed for blindness
- Why he would never touch a peptide
- Whether we'll need human scientists in 20 years
- What's stopping America in drug discovery
Connect with us here:
Samuel Rodriques: linkedin.com/in/samuel-g-rodriques-080a9b22
Edison Scientific: linkedin.com/company/edison-scientific
Lukas Biewald: linkedin.com/in/lbiewald
Weights & Biases: linkedin.com/company/wandb
(00:00:00) Trailer
(00:00:59) Introduction
(00:01:29) Origins and the role of nonprofits in technology
(00:12:19) Where AI is strong and weak in science
(00:25:57) Changing drug discovery
(00:31:46) Peptides and clinical trial processes
(00:46:18) Using AI to synthesize medical research
(00:52:18) How frontier models differ for specialized tasks
(01:08:15) Will AI ever replace Nobel laureates
(01:10:13) Raising $70 million from pharma investors
(01:13:16) Is this time different for AI in drug discovery
Samuel Rodriques, Co-founder of Edison Scientific, left physics because there were no unsolved problems left.
Instead, he built an AI scientist named Kosmos to cure every disease, solve aging, and map the human brain.
In this episode:
- The cure his AI proposed for blindness
- Why he would never touch a peptide
- Whether we'll need human scientists in 20 years
- What's stopping America in drug discovery
Connect with us here:
Samuel Rodriques: linkedin.com/in/samuel-g-rodriques-080a9b22
Edison Scientific: linkedin.com/company/edison-scientific
Lukas Biewald: linkedin.com/in/lbiewald
Weights & Biases: linkedin.com/company/wandb
(00:00:00) Trailer
(00:00:59) Introduction
(00:01:29) Origins and the role of nonprofits in technology
(00:12:19) Where AI is strong and weak in science
(00:25:57) Changing drug discovery
(00:31:46) Peptides and clinical trial processes
(00:46:18) Using AI to synthesize medical research
(00:52:18) How frontier models differ for specialized tasks
(01:08:15) Will AI ever replace Nobel laureates
(01:10:13) Raising $70 million from pharma investors
(01:13:16) Is this time different for AI in drug discovery










